Large increase in a Dutch woman’s lifetime risk of developing breast cancer

Paap, Ellen; Broeders, Mireille J. M.; Schoor, Guido van; Otten, J.D.M.; Verbeek, A.L.M.

doi:10.1016/j.ejca.2008.04.008

Cited by 15 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In The Netherlands, the lifetime risk to develop breast cancer increased in the last decades from 1 in 10 in 1989 to 1 in 7 in 2003 [1]. In parallel, the annual number of newly diagnosed cases of breast cancer rose to over 13,000 in 2008 [2].…”

Section: Introductionmentioning

confidence: 99%

Immunophenotyping invasive breast cancer: paving the road for molecular imaging

et al. 2012

View full text Add to dashboard Cite

BackgroundMammographic population screening in The Netherlands has increased the number of breast cancer patients with small and non-palpable breast tumors. Nevertheless, mammography is not ultimately sensitive and specific for distinct subtypes. Molecular imaging with targeted tracers might increase specificity and sensitivity of detection. Because development of new tracers is labor-intensive and costly, we searched for the smallest panel of tumor membrane markers that would allow detection of the wide spectrum of invasive breast cancers.MethodsTissue microarrays containing 483 invasive breast cancers were stained by immunohistochemistry for a selected set of membrane proteins known to be expressed in breast cancer.ResultsThe combination of highly tumor-specific markers glucose transporter 1 (GLUT1), epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF1-R), human epidermal growth factor receptor 2 (HER2), hepatocyte growth factor receptor (MET), and carbonic anhydrase 9 (CAIX) 'detected' 45.5% of tumors, especially basal/triple negative and HER2-driven ductal cancers. Addition of markers with a 2-fold tumor-to-normal ratio increased the detection rate to 98%. Including only markers with >3 fold tumor-to-normal ratio (CD44v6) resulted in an 80% detection rate. The detection rate of the panel containing both tumor-specific and less tumor-specific markers was not dependent on age, tumor grade, tumor size, or lymph node status.ConclusionsIn search of the minimal panel of targeted probes needed for the highest possible detection rate, we showed that 80% of all breast cancers express at least one of a panel of membrane markers (CD44v6, GLUT1, EGFR, HER2, and IGF1-R) that may therefore be suitable for molecular imaging strategies. This study thereby serves as a starting point for further development of a set of antibody-based optical tracers with a high breast cancer detection rate.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunophenotyping invasive breast cancer: paving the road for molecular imaging

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Such estimates are commonly used benchmarks with regard to other chronic diseases, such as cardiovascular disease and cancer, but they have not until recently been adopted in COPD [4,5].…”

Section: Introductionmentioning

confidence: 99%

Trends in the lifetime risk of COPD exacerbation requiring hospitalisation

et al. 2013

View full text Add to dashboard Cite

This study aimed to estimate time trends in the lifetime risk of hospitalisation with exacerbation of chronic obstructive pulmonary disease (COPD) in Denmark.During the period from 1994 to 2008, a register-based cohort study was conducted covering each subject in the entire population of Denmark (5.18 million in 2008). Based on previously validated diagnosis codes, all COPD hospitalisations were identified. Individual retrospective review periods of 8 years were used to determine first-time hospitalisations. From year 2002 to 2008, all first-time COPD hospitalised subjects aged o30 years were identified. The calculation of lifetime risk was based on age-and sex-specific first-time COPD hospitalisation rates and rates of COPD hospitalisation-free survival, assuming them to be calendar time stationary.The study included 23.9 million person-years of risk time and identified 48 959 first-time COPD hospitalisations. For 30-year-olds in Denmark, the lifetime risk of COPD hospitalisation was 12.0% (95% CI 11.9-12.2) for females and 10.9% (95% CI 10.8-11.1) for males. Trends were generally equal in both sexes.During the period from 2002 to 2008, the rate of first-time COPD hospitalisations decreased, while the survival of never COPD hospitalised subjects increased. In consequence, the lifetime risk of COPD hospitalisation remained constant. @ERSpublications A 10% lifetime risk of COPD hospitalisation remains constant

show abstract

“…In the Netherlands, the incidence is 1.58 per 1000 women and the prevalence is 11.61 per 1000 womenwhich means that 1 in 7 women in the Netherlands will have breast cancer during their lifetime. 10,11 Given the high incidence of breast cancer in the general population, it is possible that an unexpected occult carcinoma could be detected during the pathologic examination following elective breast surgery, such as capsulectomy. In fact, occult carcinomas are known to be found in breast reduction specimens.…”

Section: Discussionmentioning

confidence: 99%